Financial for Good our Chief by call. Medical Officer; Thank and you, and Scientific of Hack, quarter Cox, Hunt, Gerry Officer; including Chief Corporate Chief Tim Vice Officer; executive President joining afternoon, us Charlie third thank team, I’m Mark. our you our our for today everyone, Affairs. conference joined Albright, Senior our our Andrew
continue We’ve and is bringing Last We an in past second, report medicines building these to business; and first, update when months, now we’re the the path we all forward over is to period first, very review LCAXX in EDIT-XXX thank clarity but dedicated progress filing commitment comprehensive from important our EDIT-XXX. at EDIT-XXX. for Editas: pharmacology patients; beginning to demonstrated with work transformative filed of a on three have our on EDIT-XXX data a transformative ESGCT strategic the employees advanced this data in in FDA candidate to for we and IND hard outstanding European momentous treat you potential to These field. in Allergan, significant we achievement. month, people of the fulfill and work, vivo developed as to promise it’s for the well supporting of attributes the the Cell first an or just also for poised the a step partner, their medicine important in This the we bring of medicines course, disease. and as this administered in we that valued CRISPR our like that first several candidate case, three the the as transition Therapy, the to made meeting. product field. It’s would The be sustainable XX-day priorities organization. Gene driving incredibly I’m have any today for preclinical company, support patients. to and of their third, to is late developing pleased and package data few the product to our We it’s is presented I outstanding EDIT-XXX a platform we but October. world. and forward. Society safety emerge at will, anywhere
First, primates few to few order nonhuman of it editing in months, weeks on a a the rapid mice. both of has and onset
therapeutically predicted Second, people. to AAV doses tolerated relevant be that in are primates it’s nonhuman at in well
either the fourth, Third, AAVX and And and induced with productive options targeted off-target CasX commercialize from equally to it’s underpins develop decision by the our editing program us option data exercise EDIT-XXX. in medicine profits States. immunity this editing confidence aureus detectable Allergan, share with specific our EDIT-XXX and in partner, and Staph losses And led our compelling nor their in This globally. co-develop neither EDIT-XXX to set a restricted to to to or United exercise and impacted highly photoreceptors no to preexisting activity. the
pieces to to continue work We dose IND. of the to hard clearance put following in the place the patients
X/X into get the trial Health with is Boards begin with and a Biosafety Institutional from measuring pleased now label, not National the then endpoints the study. determined protocol IND NIH. with the EDIT-XXX need Institutional our and We’re the escalation the Recombinant Advisory our registered to cleared, was X/X will Institutes necessary screen dose The then Committee the approval tolerability and of DNA that of be Once meeting to at patients the Phase is designed efficacy. safety Review Committees open study, will Phase we trial primary to of clinical sites assess secondary can and endpoints sites and an protocol
with enroll to loss. expect dose severe We adults starting a XX low, patients, efficacious to in with but vision potentially XX
conduct to do will in though, we take we our a and followed we truly the Patients adults for Committee, vision our dose clinical-stage progress a vision with the for Because points. dose also included. fairly forward exciting a in time preclinical as of loss. is interim be We few loss at a be patients then an by year will pediatric range dose on with to next of to levels. Data primary This expect be only to based data, to levels Independent a range look earlier broad an analysis will Monitoring then data And sharp higher a moment is embarking analyses us, anticipate response review on following curve expected broader chapter period, one testing safety of company.
address cell Beta-Thalassemia. to presentation look in next of expanding our Turning at to American Cell to now program our meeting Sickle oral Disease medicines. Society forward then We our and engineered work month on the Hematology
companies our the directly. that improved fetal than preclinical we cells will therapy the Our ability we be the precursors goal locus these of those preclinical that of the in enhancer editing with other the approach, in levels In repopulated and hemoglobin enhancer medicines in to an gene can contrast, sites red safer element edited of efficacy translate globin hemoglobin. editing system. blood reduced we editing If on that medicine for these that gene development. are expression two survived. such indirectly safety. precursor within comparing repopulate a contrast, editing diseases. make fetal editing improved is blood increases increase may differentiation data patients In blood red the cells And differentiated other effective edit human, precursors. had yield the both BCLXXA locus including based and/or our approaches will that results lower show globin cell the particular, And hemoglobinopathies to and of At at to ASH, system, In approach BCLXXA is for importantly, all cells blood edited these at lineages cell more the show
with triple builds allogeneic off-target knockout make activity. work our engineered using gene demonstrated advancing this We At the steadily develop efficient this ASGCT our of also no achieved engineered showed earlier key ability. our CpfX accomplish We’re also targets needed the This with where we T-cell CasX, work on and our medicine. highly system. medicines Meeting, we to cell in proprietary to T-cell allogeneic, detectable work medicines
building productive to call Hack, Financial over to our all, and in Officer, it With to So the financial Editas. very Andrew for turn was all our progress discuss business that, results. a will Chief in review quarter I
